Matrix metalloproteinase 13 genotype in rs640198 polymorphism is associated with severe coronary artery disease

Anna Vaškůa, Jaroslav Meluzínb, Jan Blahák, Vladimír Kinelb, Monika Pávková Goldbergová, Jan Sitarb, Filip Zlámal, Julie Bienertová-Vaškůa and Jiří Vítovecb

aDepartment of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
b1st. Department of Internal Medicine/Cardioangiology, ICRC, St. Anna Hospital, Masaryk University, Brno, Czech Republic

Abstract. Atherosclerosis as a main etiopathogenetic source for coronary artery disease (CAD) development is intimately related to dynamic changes in the extracellular matrix (ECM). Elevated levels of MMP-13 have been observed in human atherosclerotic plaques which could also involve variability in MMP-13 gene. The aim of the study was to associate rs640198 polymorphism with CAD and/or with its severity.

The study comprised 1071 consecutive patients with suspected or known coronary artery disease (CAD), confirmed by coronary angiography.

Genotyping for the rs640198 polymorphism in MMP-13 gene was performed using Taqman® assay. The TT and TG genotypes of rs640198 polymorphism in MMP-13 gene confer the significantly increased risk of triple vessel disease compared to patients without atherosclerotic lesions in coronary arteries (odds ratio = 1.64, Pcorr = 0.05). Furthermore, an increased risk of having 5 and more stenoses (odds ratio = 1.90, Pcorr = 0.004) was observed in TT and TG carriers (sensitivity of 0.613 and a specificity of 0.544; power of the test is 0.87).

The T allele of MMP-13 intron polymorphism rs640198 is associated with the severity of coronary artery disease, represented by the number of affected arteries as well as by the number of stenoses confirmed by coronarography.

Keywords: MMP-13, CAD, rs640198, severity

1. Introduction

The cardiovascular diseases, especially the coronary artery disease (CAD), represent one of the most common causes of mortality in developed countries. The genetic background that underlies the susceptibility, occurrence and severity of CAD, however, is still poorly elucidated [10].

Atherosclerotic process as a base for CAD onset is intimately related to dynamic changes in the extracellular matrix (ECM) and its associated proteins: the retention of lipoproteins by proteoglycans leads to the development of atherosclerotic lesions, but ultimately, it is the breakdown of ECM that facilitates plaque ruptures, triggering the onset of clinical symptoms of CAD [8]. The stability of the plaque depends on its collagen content; degradation of the collagen leads to a vulnerable plaque that is prone to rupture [4]. Therefore, matrix metalloproteinases (MMPs) which are able to cleave collagens should play an important role in the pathogenesis of atherosclerosis, plaque rupture and aneurysm [16,21]. The expression of various MMPs, along with their endogenous inhibitors, seems to be differentially regulated dependently on the lesion progression [30].

MMP-13 is active against types I and III collagens [11,18]. MMP-13 can be further distinguished from other interstitial collagenases by its ability to
cleave gelatin, proteoglycans, tenascin, fibronectin, as well as its capacity to activate latent proMMPs [13]. It seems to have a unique role in the accelerated collagen turnover associated with various conditions [18].

The intimal macrophages seem to be the major source of MMP-13 production [27,30]. MMP-13 colocalized with MMP-1 in human atheroma is localized mostly in the shoulder region of the plaques as well as in areas surrounding the lipid core. Levels of MMP-1 as well as MMP-13 in atheromatous plaques exceed those in fibrous plaques, corresponding to the content of macrophages [27]. The increased expression of MMPs in the atheroma also leads to increased MMP levels in the circulation [4].

Late AT II (angiotensin II) treatment was reported to augment lesion size of fully developed atherosclerotic plaques with macrophage-rich phenotype in ApoE null mice atherosclerotic model [6]. Amplified collagen type I degradation in this case is related to increase of active MMP-8 and MMP-13 levels in the macrophage-rich plaque [6].

However, MMP-13 was also proposed as another possible candidate for the NO-mediated prevention of atherosclerosis in the model of atherosclerotic NO/SOD/apoE-null mice: MMP-13 is able to cleave ICAM-1, both in vivo and in vitro [28]. Increased levels of soluble ICAM-1 (together with VCAM-1, E-selectin and P-selectin) as markers of inflammation were associated with the development of atherosclerosis and clinical expression of CAD [16]. An antiatherogenic effect of MMP-13 is further documented by its ability to process human prolactin in vitro to a 16-kDa fragment with strong antiangiogenic properties [17] and by degrading MCP-3 which is functioning as a potent proinflammatory stimulus in atherosclerotic lesions [19].

MMP13 gene is encoded by a 10.5 kilobase gene located on human chromosome 11q22.2–q22.3 [21]. Sequence analysis of the 5'-flanking region of the gene revealed the presence of a TATA box, an AP-1 motif, a PEA-3 consensus motif, an osteoblast specific element (OSE-2) and a TGF-β inhibitory element [20,22].

MMP-13 expression was observed to be nearly absent in the normal arterial wall, but was found to be remarkably increased with atherosclerotic lesion progression [27,30] which could be caused by variability of MMP-13 gene. So far, six polymorphisms in MMP-13 gene were identified (ALFRED, http://alfred.med.yale.edu/alfred/recordinfo.asp?condition=sites.site_uid= 'SI001554P). The intron rs640198 polymorphism was chosen for sufficiently high frequency of the polymorphism in European population (ALFRED). Further-
Table 1: Descriptive statistics of major variables in different MMP-13 genotypes

<table>
<thead>
<tr>
<th></th>
<th>MMP-13 GG (N = 521)</th>
<th>MMP-13 GT (N = 459)</th>
<th>MMP-13 TT (N = 91)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (median, range)</td>
<td>41 (12–94)</td>
<td>41 (18–104)</td>
<td>40 (18–61)</td>
<td>0.582</td>
</tr>
<tr>
<td>Sex (M/F, % of men)</td>
<td>360 (69%)</td>
<td>309 (67%)</td>
<td>65 (71%)</td>
<td>Pg = 0.689 Pa = 0.975</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>325 (62%)</td>
<td>270 (59%)</td>
<td>57 (63%)</td>
<td>Pg = 0.490 Pa = 0.347</td>
</tr>
<tr>
<td>Hypertension</td>
<td>418 (80%)</td>
<td>357 (78%)</td>
<td>75 (82%)</td>
<td>Pg = 0.481 Pa = 0.840</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>154 (30%)</td>
<td>143 (31%)</td>
<td>30 (33%)</td>
<td>Pg = 0.752 Pa = 0.455</td>
</tr>
<tr>
<td>Obesity</td>
<td>172 (33%)</td>
<td>123 (27%)</td>
<td>31 (34%)</td>
<td>Pg = 0.08 Pa = 0.230</td>
</tr>
<tr>
<td>Smoking</td>
<td>66 (13%)</td>
<td>65 (14%)</td>
<td>19 (21%)</td>
<td>Pg = 0.113 Pa = 0.07</td>
</tr>
<tr>
<td>Family history of CAD or stroke before age of 60 years (N = 868)</td>
<td>98 (N = 420, 23%)</td>
<td>68 (N = 373, 18%)</td>
<td>14 (N = 75, 19%)</td>
<td>Pg = 0.188 Pa = 0.108</td>
</tr>
<tr>
<td>CAD</td>
<td>398 (76%)</td>
<td>368 (80%)</td>
<td>79 (87%)</td>
<td>Pa = 0.02 Pg = 0.06</td>
</tr>
</tbody>
</table>

CAD = coronary artery disease.
Pg: probability of a difference in genotype distribution.
Pa: probability of a difference in allelic frequencies.

insignificant coronary atherosclerosis (stenoses with lumenal diameter narrowing below 50% or luminal irregularities), and patients with normal smooth coronary arteries. In addition, the absolute number of significant coronary artery stenoses (irrespective of the vessels involved) was calculated.

Another 203 healthy individuals with negative cardiovascular disease history were recruited from general practitioner office.

2.2. Analysis of MMP-13 polymorphism (rs640198)

To analyse polymorphism, blood samples were drawn and stored at a temperature below −18°C. The DNA was extracted from periphery blood leukocytes using proteinase K and precipitated by isopropanol and chloroform. DNA was extracted from peripheral leukocytes by using the standard proteinase K method. MMP-13 gene polymorphism rs640198, T/G in position 6373, on the chromosome 11 was detected in the study.

Genotyping of rs640198 polymorphism in MMP-13 gene was performed using 5’ exonuclease (Taqman®) chemistry on the ABI Prism® 7000 (Applied Biosystems, Foster City, CA). All assays were validated by direct sequencing using Big Dye v 1.1 terminator chemistry (Applied Biosystems).

2.3. Analysis of MMP-13 plasma levels

Plasma concentrations of MMP-13 were determined by ELISA in 20 healthy individuals.

2.4. Statistical analysis

Continuous variables are given as a median and range; categorical variables are presented as numbers (percentage). For analysis of differences among the groups, non-parametric test (Mann-Whitney U test, Kruskal-Wallis ANOVA test) or Fisher’s exact test were chosen. The distributions of genotype and allelic frequencies and their differences were calculated using chi-square test. The Bonferroni correction (Pcorr) for multiple comparisons was used when necessary.

Linear regression model was used to create multivariate model of relationships among MMP-13 genotype (GG+GT vs. TT), age, sex, HDL, CRP and statins therapy.

Statistical package Statistica, Version 9 was used for analyses. A $p < 0.05$ was considered significant.

3. Results

Basic description of the study cohort according to the genotyped of investigated polymorphism is given in Table 1, we found a marginally significant differ-
46  V. Anna et al. / Matrix metalloproteinase 13 genotype in rs640198 polymorphism is associated with severe coronary artery disease

<table>
<thead>
<tr>
<th>No of affected arteries</th>
<th>MMP-13-TT</th>
<th>MMP-13-TG</th>
<th>MMP-13-GG</th>
<th>Frequency of alleles T/G</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAD1 (N = 252)</td>
<td>24 (10%)</td>
<td>101 (40%)</td>
<td>127 (50%)</td>
<td>0.296/0.704</td>
</tr>
<tr>
<td>CAD2 (N = 252)</td>
<td>20 (8%)</td>
<td>108 (43%)</td>
<td>124 (49%)</td>
<td>0.294/0.706</td>
</tr>
<tr>
<td>CAD3 (N = 272)</td>
<td>29 (11%)</td>
<td>127 (46%)</td>
<td>116 (43%)</td>
<td>0.340/0.660</td>
</tr>
<tr>
<td>CAD4 (N = 69)</td>
<td>6 (9%)</td>
<td>32 (46%)</td>
<td>31 (45%)</td>
<td>0.319/0.681</td>
</tr>
<tr>
<td>Non CAD5 (N = 106)</td>
<td>8 (8%)</td>
<td>41 (39%)</td>
<td>57 (53%)</td>
<td>0.269/0.731</td>
</tr>
<tr>
<td>Non CAD6 (N = 120)</td>
<td>4 (3%)</td>
<td>50 (42%)</td>
<td>66 (55%)</td>
<td>0.242/0.758</td>
</tr>
<tr>
<td>All groups (N = 1071)</td>
<td>91 (8%)</td>
<td>459 (43%)</td>
<td>521 (49%)</td>
<td>0.300/0.700</td>
</tr>
<tr>
<td>Healthy control group</td>
<td>21 (10%)</td>
<td>79 (39%)</td>
<td>103 (51%)</td>
<td>0.298/0.702</td>
</tr>
</tbody>
</table>

Pg: probability of a difference in genotype distribution.
Pcorr, Pacorr: P-values corrected for multiple comparison.

Table 2

Table 2: Number of affected arteries and MMP-13 genotypes

When CAD group had been further stratified according to the number of affected arteries, significant differences in MMP-13 genotype distribution as well as in allelic frequency between patients with triple vessel disease (CAD 3) and persons without affection of coronary arteries (Non-CAD 6) were observed (Pcorr = 0.01, Pacorr = 0.06, Table 1).

Furthermore, we evaluated the prevalence of congenital vascular abnormalities and their association with rs640198 polymorphism in our group of patients. Although aortic aneurysm was identified only in 7 patients (= 0.7%), the increased frequency of the T allele was observed in this small group (Pa = 0.03, data not shown). The GT genotype was almost four times more frequent in 23 (2%) patients with pulmonary embolism (OR = 3.88, Pcorr = 0.007) compared to CAD patients without pulmonary embolism with sensitivity 0.74, specificity 0.59; power test was 0.84 (data not shown).

The MMP-13 plasma levels were evaluated in 20 healthy individuals: only very low levels of the matrix metalloproteinase-13 were detected (0.021 ± 0.01 ng/mL). No significant differences among MMP-13 genotypes were observed in the group (P = 0.571).

4. Discussion

In our previous study, two different haplotypes in promoter of MMP-2 gene were observed to be significantly more or less frequent in persons with coronary triple vessel disease compared to non-ischemic persons [29]. In the present study, the rs640198 (intronic) polymorphism in MMP-13 gene was associated with triple vessel disease and also with presence of five and more stenoses of coronary arteries. Functional consequence between MMP-2 and MMP-13 can be considered, as MMP-2 is able to activate MMP-13s from
to be substantially affected by blood flow characteristics. The total MMP:TIMP ratio; this relation was shown to be caused by the atherosclerotic process (elastin: collagen), in agreement with the recent findings that polymorphisms in MMP2, MMP3, MMP-13, and ELN genes significantly determine the structural remodelling of vessel wall during extracellular matrix [3]. It has been reported previously that not only MMPs expression or the blood levels of MMPs and their inhibitors, but also blood flow characteristics must be considered when vascular remodelling during atherosclerosis is evaluated [2].

Another aspect of great importance could be the prenatal role of the MMP-13 during organogenesis of cardiovascular system [1]. Recently, the MMP-13 (RNA as well as protein) was observed to be significantly downregulated during the second and the third trimester of pregnancy with respect to diversity and amount of matrix metalloproteinases produced and secreted by human decidua and invasive trophoblast [1]. This could have crucial effects on embryonic development of cardiovascular system, as MMP13 may be involved in early stages of cardiovascular development [1]. The supposed decreased function of the T allele of rs640198 MMP-13 polymorphism associated with the loss of Pbx-1 transcription factor site [5] could be related to suboptimal MMP-13 expression and therefore could play a role in early stages of heart development.

Based on this hypothesis and also on results of the presented study, another question arises as for possible consequence of CAD with some congenital heart malformations, even though below clinical significance. Recently, when the multidetector computed tomography (MDCT) angiography was used for CAD screening in a large general cardiology cohort (N = 4,543), other clinically relevant nonatherosclerotic cardiovascular diseases were visualized and identified unexpectedly [14] in 4.4% of investigated subjects (N = 200). Most common abnormalities were: congenital coronary artery anomalies (38%, largely right coronary artery from the left aortic sinus); ascending aortic aneurysms > or = 45 mm (22%); hypertrophic cardiomyopathy with apical left ventricular (LV) wall thickening (14%); valvular heart diseases (8%), congenital heart diseases, including ventricular septal defect (6%); pulmonary embolus (6%); as well as LV noncompaction, left atrial myxoma, and LV apical aneurysm (2% each).

In our study, the T allele of the investigated polymorphism in MMP13 gene was more frequent in patients with aortic aneurysma and pulmonary embolism. This is in agreement with the recent findings that polymorphisms in MMP2, MMP3, MMP-13, and ELN genes may independently contribute to the pathogenesis of abdominal aortic aneurysma [23,24]. The structural changes in the venous wall in addition to the increased expression of MMP-2, MMP-9 and MMP-13 in venous aneurysm with pulmonary embolism compared to normal saphenous vein and varicous vein suggest a possible causal role for these MMPs in pathogenesis of these states [12]. Even though there is no evidence of the functional impact of the investigated polymorphism, proMMP-13 and coordinate their proteolytic activities on extracellular matrix [3]. It has been reported previously that the structural remodelling of vessel wall during atherosclerotic process (elastin: collagen) is dictated by total MMP:TIMP ratio; this relation was shown to be substantially affected by blood flow in experimental study on adult male Sprague-Dawley rats [2]. Based on the results of this study, it can be concluded that not only MMPs expression or the blood levels of MMPs and their inhibitors, but also blood flow characteristics must be considered when vascular remodelling during atherosclerosis is evaluated [2].

Table 3
Number of significant stenoses and MMP-13 genotypes

<table>
<thead>
<tr>
<th>No of significant stenoses</th>
<th>MMP-13-TT</th>
<th>MMP-13-TG</th>
<th>MMP-13-GG</th>
<th>Frequency of alleles T/G</th>
<th>Pg</th>
<th>Pa</th>
<th>Pg-corr</th>
<th>Pa-corr</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 5 (N = 163)</td>
<td>14 (9%)</td>
<td>86 (53%)</td>
<td>63 (38%)</td>
<td>0.350/0.750</td>
<td>0.008</td>
<td>0.004</td>
<td>0.04</td>
<td>0.02</td>
</tr>
<tr>
<td>4 (N = 123)</td>
<td>10 (8%)</td>
<td>54 (44%)</td>
<td>59 (48%)</td>
<td>0.301/0.699</td>
<td>0.308</td>
<td>0.188</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 (N = 187)</td>
<td>22 (12%)</td>
<td>67 (36%)</td>
<td>98 (52%)</td>
<td>0.297/0.703</td>
<td>0.06</td>
<td>0.174</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 (N = 167)</td>
<td>12 (7%)</td>
<td>76 (46%)</td>
<td>79 (47%)</td>
<td>0.299/0.701</td>
<td>0.346</td>
<td>0.162</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 (N = 205)</td>
<td>21 (10%)</td>
<td>85 (42%)</td>
<td>99 (48%)</td>
<td>0.310/0.690</td>
<td>0.120</td>
<td>0.07</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 (N = 226)</td>
<td>12 (5%)</td>
<td>91 (40%)</td>
<td>123 (54%)</td>
<td>0.254/0.746</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All groups (N = 1071)</td>
<td>91 (8%)</td>
<td>459 (43%)</td>
<td>521 (49%)</td>
<td>0.300/0.700</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Pg: probability of a difference in genotype distribution. Pa: probability of a difference in allelic frequencies. Pgcorr, Pacorr: P-values corrected for multiple comparison.

Table 4
Multiple logistic regression analysis for the association between MMP-13 rs640198 genotypes and susceptibility to CAD adjusting for confounding factors

<table>
<thead>
<tr>
<th></th>
<th>Adjusted OR (95% CI)</th>
<th>P -value</th>
</tr>
</thead>
<tbody>
<tr>
<td>MMP-13</td>
<td>1.34 (0.76–2.38)</td>
<td>0.31</td>
</tr>
<tr>
<td>T allele</td>
<td></td>
<td></td>
</tr>
<tr>
<td>carriage</td>
<td>(TT and GT)</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td>0.19 (0.10–0.37)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>(women vs. men)</td>
<td>1.06 (1.04–1.09)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>HDL</td>
<td>0.26 (0.12–0.56)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>CRP</td>
<td>1.03 (1–1.06)</td>
<td>0.006</td>
</tr>
<tr>
<td>Statins</td>
<td>57.78 (31.97–104.43)</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

HDL – high density lipoproteins. CRP – C-reactive protein.
Based on the results of the presented studies, we believe that these findings support functional, not only statistical association of rs640198 MMP-13 polymorphism with coronary artery disease and pulmonary embolism and aortic aneurysm, observed in our study.

Moreover, other polymorphisms in other MMP genes, especially in MMP-3 and MMP-9 gene, have been previously reported to associate with the manifestation of coronary atherosclerosis and/or its progression, coronary restenosis development after therapy and plaques instability responsible for myocardium infarction development [7,9,25,31]. Certain genotypes of MMP-1, MMP-3 and MMP-9 with lower transcriptional activity were also associated with higher frequencies of arteriovenous fistula (AVF) failure in hemodialysis patients which may result from more accumulation of extracellular matrix, leading to AVF stenosis [15].

No information about MMP-13 levels in CAD have been reported so far in humans. However, MMP-2 as well as MMP-13 expression was found to be different in aorta, carotid artery, femoral artery and vena cava in animal model [2] which seemed to decrease the potential predictive value of MMP-13 blood levels. In a nother study, plasma levels of MMP-8 were associated with CAD [11].

Recently, a comprehensive analysis of extracellular matrix components comprising the vascular proteome in humans was performed [8]. The proteomics method allowed for the identification of scarce proteins present in the vascular extracellular space, identification of novel glycoproteins, and interrogation of proteolytic activity within tissues based on the identification of proteolytic enzymes and corresponding degradation products. These facts, if comprehensively characterized, could lead to development of the new therapeutic options for cardiovascular diseases [8].

In conclusion, the T allele of rs640198 polymorphism in MMP-13 gene was in our study associated with the severity of coronary artery disease characterized by the number of affected arteries as well as by the number of confirmed stenoses. More research into the pathophysiological role of MMP13 in early development of cardiovascular system as well as in pathophysiology of coronary artery disease and other adverse cardiovascular conditions is necessary.

Acknowledgement

The study was supported by a grant of the Internal Grant Agency of the Czech Republic IGA NS/102063/2009.

References


Submit your manuscripts at http://www.hindawi.com